Cost–effectiveness of palivizumab in infancy

References

• La Rosa AM, Whimbey E. Respiratory viruses. In: Infectious Diseases (2nd Revised Edition). Cohen J, Powderley WJ (Eds). Elsevier Health Sciences, Chapter 220, 2074–2076 (2004).
   Google Scholar
• Mims C, Dockrell HM, Goering RV et al. Lower respiratory tract infections. In: Medical Microboiology (3rd Revised Edition). Mims C, Dockrell H, Goering RH, Roitt IM, Wakelin D, Zuckerman M (Eds). Elsevier Health Sciences, Chapter 19, 219–220 (2004).
   Google Scholar
• Hall CB, McCarthy CA. Respiratory syncytial virus. In: Principles and Practice of Infectious Diseases (2). Mandell GL, Bennett JI, Dolin R (Eds). Elsevier, PA, USA 2008–2021 (2005).
   Google Scholar
• Nicholson KG, McNally T, Silverman M et al. Rates of hospitalisation for influenza, respiratory syncytial virus and human metapneumovirus among infants and young children. Vaccine24(1), 102–108 (2006).
   PubMed Web of Science ®Google Scholar
• Muller-Pebody B, Edmunds WJ, Zambon MC, Gay NJ, Crowcroft NS. Contribution of RSV to bronchiolitis and pneumonia-associated hospitalizations in English children, April 1995–March 1998. Epidemiol. Infect.129(1), 99–106 (2002).
   PubMed Web of Science ®Google Scholar
• No authors listed. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. The PREVENT Study Group. Pediatrics99(1), 93–99 (1997).
   PubMed Web of Science ®Google Scholar
• No authors listed. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics102(3 Pt 1), 531–537 (1998).
   PubMed Web of Science ®Google Scholar
• Deshpande SA, Northern V. The clinical and health economic burden of respiratory syncytial virus disease among children under 2 years of age in a defined geographical area. Arch. Dis. Child.88(12), 1065–1069 (2003).
   PubMed Web of Science ®Google Scholar
• Clark SJ, Beresford MW, Subhedar NV, Shaw NJ. Respiratory syncytial virus infection in high risk infants and the potential impact of prophylaxis in a United Kingdom cohort. Arch. Dis. Child.83(4), 313–316 (2000).
   PubMed Web of Science ®Google Scholar
• Carbonell-Estrany X, Quero J, Group IS. Hospitalization rates for respiratory syncytial virus infection in premature infants born during two consecutive seasons. Pediatr. Infect. Dis. J.20(9), 874–879 (2001).
   PubMed Web of Science ®Google Scholar
• Zaw W, McDonald J. Respiratory syncytial virus bronchiolitis in ex-preterm infants in the Scottish highlands: review of hospital admissions and an analysis of hospital cost. Scott. Med. J.48(4), 108–110 (2003).
   Google Scholar
• Heikkinen T, Valkonen H, Lehtonen L, Vainionpaa R, Ruuskanen O. Hospital admission of high risk infants for respiratory syncytial virus infection: implications for palivizumab prophylaxis. Arch. Dis. Child. Fetal Neonatal Ed.90(1), F64–F68 (2005).
   PubMedGoogle Scholar
• Thompson WW, Shay DK, Weintraub E et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA289(2), 179–186 (2003).
   PubMed Web of Science ®Google Scholar
• Fleming DM, Pannell RS, Cross KW. Mortality in children from influenza and respiratory syncytial virus. J. Epidemiol. Community Health59(7), 586–590 (2005).
   PubMed Web of Science ®Google Scholar
• Feltes TF, Cabalka AK, Meissner HC et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J. Pediatr.143(4), 532–540 (2003).
   PubMed Web of Science ®Google Scholar
• American Academy Of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics112(6 Pt 1), 1442–1446 (2003).
   PubMed Web of Science ®Google Scholar
• Northway WH Jr, Rosan RC, Porter DY. Pulmonary disease following respirator therapy of hyaline-membrane disease: bronchopulmonary dysplasia. N. Engl. J. Med.276(7), 357–368 (1967).
   PubMed Web of Science ®Google Scholar
• Walsh MC, Yao Q, Gettner Pet al. Impact of a physiologic definition on bronchopulmonary dysplasia rates. Pediatrics114(5), 1305–1311 (2004).
   PubMed Web of Science ®Google Scholar
• Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am. J. Respir. Crit. Care Med.163(7), 1723–1729 (2001).
   PubMedGoogle Scholar
• Carbonell-Estrany X, Quero J, Bustos G et al. Rehospitalization because of respiratory syncytial virus infection in premature infants younger than 33 weeks of gestation: a prospective study. IRIS Study Group. Pediatr. Infect. Dis. J.19(7), 592–597 (2000).
   PubMed Web of Science ®Google Scholar
• Resch B, Pasnocht A, Gusenleitner W, Muller W. Rehospitalisations for respiratory disease and respiratory syncytial virus infection in preterm infants of 29–36 weeks gestational age. J. Infect.50(5), 397–403 (2005).
   Google Scholar
• Groothuis JR, Simoes EA, Levin MJ et al. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group. N. Engl. J. Med.329(21), 1524–1530 (1993).
   PubMed Web of Science ®Google Scholar
• Stevens TP, Sinkin RA, Hall CB, Maniscalco WM, McConnochie KM. Respiratory syncytial virus and premature infants born at 32 weeks’ gestation or earlier: hospitalization and economic implications of prophylaxis. Arch. Pediatr. Adolesc. Med.154(1), 55–61 (2000).
   PubMed Web of Science ®Google Scholar
• Subramanian KN, Weisman LE, Rhodes T et al. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group. Pediatr. Infect. Dis. J.17(2), 110–115 (1998).
   PubMed Web of Science ®Google Scholar
• Saez-Llorens X, Castano E, Null D et al. Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. The MEDI-493 Study Group. Pediatr. Infect. Dis. J.17(9), 787–791 (1998).
   PubMed Web of Science ®Google Scholar
• Lacaze-Masmonteil T, Seidenberg J, Mitchell I et al. Evaluation of the safety of palivizumab in the second season of exposure in young children at risk for severe respiratory syncytial virus infection. Drug Saf.26(4), 283–291 (2003).
   Google Scholar
• Grimaldi M, Gouyon B, Sagot P et al. Palivizumab efficacy in preterm infants with geatational age ≤ 30 weeks without bronchopulmonary dysplasia. Pediatr. Pulmonol.42, 189–192 (2007).
   PubMed Web of Science ®Google Scholar
• Mitchell I, Tough S, Gillis L, Majaesic C. Beyond randomized controlled trials: a “real life” experience of respiratory syncytial virus infection prevention in infancy with and without palivizumab. Pediatr. Pulmonol.41(12), 1167–1174 (2006).
   PubMed Web of Science ®Google Scholar
• Shireman TI, Braman KS. Impact and cost–effectiveness of respiratory syncytial virus prophylaxis for Kansas medicaid’s high-risk children. Arch. Pediatr. Adolesc. Med.156(12), 1251–1255 (2002).
   PubMed Web of Science ®Google Scholar
• Sorrentino M, Powers T. Effectiveness of palivizumab: evaluation of outcomes from the 1998 to 1999 respiratory syncytial virus season. The Palivizumab Outcomes Study Group. Pediatr. Infect. Dis. J.19(11), 1068–1071 (2000).
   PubMed Web of Science ®Google Scholar
• Roeckl-Wiedmann I, Liese JG, Grill E et al. Economic evaluation of possible prevention of RSV-related hospitalizations in premature infants in Germany. Eur. J. Pediatr.162(4), 237–244 (2003).
   PubMed Web of Science ®Google Scholar
• Thomas M, Bedford-Russell A, Sharland M. Hospitalisation for RSV infection in ex-preterm infants-implications for use of RSV immune globulin. Arch. Dis. Child.83(2), 122–127 (2000).
   PubMed Web of Science ®Google Scholar
• McCormick J, Tubman R. Readmission with respiratory syncytial virus (RSV) infection among graduates from a neonatal intensive care unit. Pediatr. Pulmonol.34(4), 262–266 (2002).
   PubMed Web of Science ®Google Scholar
• Broughton S, Bhat R, Roberts A et al. Diminished lung function, RSV infection, and respiratory morbidity in prematurely born infants. Arch. Dis. Child.91(1), 26–30 (2006).
   PubMed Web of Science ®Google Scholar
• Duppenthaler A, Gorgievski-Hrisoho M, Aebi C. Regional impact of prophylaxis with the monoclonal antibody palivizumab on hospitalisations for respiratory syncytial virus in infants. Swiss Med. Wkly131(11–12), 146–151 (2001).
   Google Scholar
• Resch B, Gusenleitner W, Muller WD, Haas J. Observational study of respiratory syncytial virus-associated hospitalizations and use of palivizumab in premature infants aged 29–32 weeks. Eur. J. Clin. Microbiol. Infect. Dis.25(2), 120–122 (2006).
   PubMed Web of Science ®Google Scholar
• Esposito S, Gasparini R, Bosis S et al. Clinical and socio-economic impact of influenza and respiratory syncytial virus infection on healthy children and their households. Clin. Microbiol. Infect.11(11), 933–936 (2005).
   PubMedGoogle Scholar
• Rackham OJ, Thorburn K, Kerr SJ. The potential impact of prophylaxis against bronchiolitis due to the respiratory syncytial virus in children with congenital cardiac malformations. Cardiol. Young15(3), 251–255 (2005).
   PubMed Web of Science ®Google Scholar
• Meberg A, Bruu AL. Respiratory syncytial virus infections in congenital heart defects – hospitalizations and costs. Acta Paediatr.95(4), 404–406 (2006).
   PubMed Web of Science ®Google Scholar
• Behrendt CE, Decker MD, Burch DJ, Watson PH. International variation in the management of infants hospitalized with respiratory syncytial virus. International RSV Study Group. Eur. J. Pediatr.157(3), 215–220 (1998).
   PubMed Web of Science ®Google Scholar
• Nuijten MJ, Wittenberg W, Lebmeier M. Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: a UK analysis. Pharmacoeconomics25(1), 55–71 (2007).
   PubMed Web of Science ®Google Scholar
• Sampalis JS, Williams JV. Morbidity and mortality after RSV-associated hospitalizations among premature canadian infants. J. Pediatr.143(Suppl. 5), S150–S156 (2003).
   PubMed Web of Science ®Google Scholar
• Joffe S, Ray GT, Escobar GJ, Black SB, Lieu TA. Cost–effectiveness of respiratory syncytial virus prophylaxis among preterm infants. Pediatrics104(3 Pt 1), 419–427 (1999).
   PubMed Web of Science ®Google Scholar
• Embleton ND; Northern Region’s Perinatal Mortality. Fetal and neonatal death from maternally acquired infection. Paediatr. Perinat. Epidemiol.15(1), 54–60 (2001).
   PubMedGoogle Scholar
• Smyth RL, Openshaw PJ. Bronchiolitis. Lancet368(9532), 312–322 (2006).
   Google Scholar
• Wenzel SE, Gibbs RL, Lehr MV, Simoes EA. Respiratory outcomes in high-risk children 7 to 10 years after prophylaxis with respiratory syncytial virus immune globulin. Am. J. Med.112(8), 627–633 (2002).
   PubMed Web of Science ®Google Scholar
• Simoes EA, Groothuis JR, Carbonell-Estrany X et al. Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing. J. Pediatr.151(1), 34–42 (2007).
   PubMed Web of Science ®Google Scholar
• Meissner HC, Long SS. Respiratory syncytial virus infection and recurrent wheezing: a complex relationship. J. Pediatr.151(1), 6–7 (2007).
   PubMed Web of Science ®Google Scholar
• Simpson S, Burls A. A systematic review of the effectiveness and cost–effectiveness of palivizumab (Synagis) in the prevention of respiratory syncytial virus (RSV) infection in infants at high risk of infection. Department of Public Health and Epidemiology, University of Birmingham, UK (2001).
   Google Scholar
• Elhassan NO, Sorbero ME, Hall CB, Stevens TP, Dick AW. Cost–effectiveness analysis of palivizumab in premature infants without chronic lung disease. Arch. Pediatr. Adolesc. Med.160(10), 1070–1076 (2006).
   PubMed Web of Science ®Google Scholar
• Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. Br. Med. J.313(7052), 275–283 (1996).
   PubMed Web of Science ®Google Scholar
• Kamal-Bahl S, Doshi J, Campbell J. Economic analyses of respiratory syncytial virus immunoprophylaxis in high-risk infants: a systematic review. Arch. Pediatr. Adolesc. Med.156(10), 1034–1041 (2002).
   PubMed Web of Science ®Google Scholar
• Kassirer JP, Angell M. The journal’s policy on cost–effectiveness analyses. N. Engl. J. Med.331(10), 669–670 (1994).
   PubMed Web of Science ®Google Scholar
• Lofland JH, O’Connor JP, Chatterton ML et al. Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: a cost–effectiveness analysis. Clin. Ther.22(11), 1357–1369 (2000).
   PubMed Web of Science ®Google Scholar
• Numa A. Outcome of respiratory syncytial virus infection and a cost–benefit analysis of prophylaxis. J. Paediatr. Child Health36(5), 422–427 (2000).
   PubMedGoogle Scholar
• Vogel AM, McKinlay MJ, Ashton Tet al. Cost–effectiveness of palivizumab in New Zealand. J. Paediatr. Child Health38(4), 352–357 (2002).
   PubMed Web of Science ®Google Scholar
• Farina D, Rodriguez SP, Bauer G et al. Respiratory syncytial virus prophylaxis: cost–effective analysis in Argentina. Pediatr. Infect. Dis. J.21(4), 287–291 (2002).
   PubMed Web of Science ®Google Scholar
• Yount LE, Mahle WT. Economic analysis of palivizumab in infants with congenital heart disease. Pediatrics114(6), 1606–1611 (2004).
   PubMed Web of Science ®Google Scholar
• Bala P, Ryan CA, Murphy BP. Hospital admissions for bronchiolitis in preterm infants in the absence of respiratory syncytial virus prophylaxis. Arch. Dis. Child. Fetal Neonatal Ed.90(1), F92 (2005).
   Web of Science ®Google Scholar
• Reeve CA, Whitehall JS, Buettner PG et al. Cost–effectiveness of respiratory syncytial virus prophylaxis with palivizumab. J. Paediatr. Child Health42(5), 253–258 (2006).
   PubMed Web of Science ®Google Scholar
• Elhassan NO, Stevens TP, Sorbero ME et al. Guidelines for palivizumab prophylaxis: are they based on infant’s risk of hospitalization for respiratory syncytial viral disease? Pediatr. Infect. Dis. J.22(11), 939–943 (2003).
   Google Scholar
• British National Formulary for children. In: British National Formulary for Children (BNFC). BMJ Publishing group, London, UK 373–374 (2006).
   Google Scholar
• Wills S, Simpson JH, Coutts J. Cost minimisation of RSV prevention with palivizumab. Arch. Dis. Child.91(8), 717 (2006).
   PubMed Web of Science ®Google Scholar
• Broughton S, Roberts A, Fox G et al. Prospective study of healthcare utilisation and respiratory morbidity due to RSV infection in prematurely born infants. Thorax60(12), 1039–1044 (2005).
   PubMed Web of Science ®Google Scholar
• Mahadevia PJ, Malinoski FJ. Cost–effectiveness of respiratory syncytial virus prophylaxis with palivizumab (Comment). Arch. Pediatr. Adolesc. Med.161, 519–520 (2007).
   Google Scholar
• Sorbero ME, Elhassan NO, Hall CB, Stevens TP, Dick AW. Cost–effectiveness of respiratory syncytial virus prophylaxis with palivizumab (author reply). Arch. Pediatr. Adolesc. Med.161(5), 519–520 (2007).
   Google Scholar
• Leidy NK, Margolis MK, Marcin JP et al. The impact of severe respiratory syncytial virus on the child, caregiver, and family during hospitalization and recovery. Pediatrics115(6), 1536–1546 (2005).
   PubMed Web of Science ®Google Scholar